首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1629868

全球計量吸入器市場 - 2025-2033

Global Metered-Dose Inhalers Market - 2025-2033

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球計量吸入器市場規模達166億美元，預計2033年將達241.8億美元，2025-2033年預測期間複合年成長率為4.8%。

定量吸入器是一種透過加壓槽將藥物輸送到肺部的裝置。它可以手動釋放，也可以吸入時自動釋放。有些吸入器有計數器來追蹤剩餘劑量。乾粉吸入器 (DPI) 是呼吸啟動的，只有透過吸入器進行深而快速的呼吸時才會釋放藥物。

市場動態：

驅動程式和限制

科技進步的崛起

由於技術進步，計量吸入器 (MDI) 市場正在不斷成長。現代 MDI 具有整合劑量計數器、智慧連接和呼吸驅動機制，解決了劑量不當和患者依從性等問題。這些創新對於氣喘和慢性阻塞性肺病等慢性疾病特別有益。轉向環保推進劑符合全球永續發展目標，並確保有效的藥物傳遞。這些改進正在增強使用者體驗、安全性和治療效果，推動對先進 MDI 的需求。

例如，2024 年 6 月，Aseptika 推出了 PUFFClicker3，這是一款與加壓計量吸入器 (pMDI) 和乾粉吸入器 (DPI) 相容的智慧吸入器劑量追蹤器。該設備支援這兩種類型的 101 個 SNOMED 編碼吸入器，使吸入器切換過程變得簡單。它為每個吸入器提供圖形說明，旨在提高所有年齡層和需要吸入器治療的呼吸系統疾病的患者的吸入器依從性。

嚴格的監管要求

由於 FDA 和 EMA 等機構的嚴格監管要求，全球計量吸入器市場面臨重大挑戰。這些法規要求嚴格的測試協議，以確保計量吸入器的安全性、有效性和品質。轉向環保推進劑使核准過程變得複雜，需要廣泛的研究和合規措施。法規核准的延遲可能會阻礙產品的推出，影響市場動態。各地區監管框架的差異也為全球擴張帶來了挑戰，為老牌企業和新興企業製造了障礙，限制了創新和市場成長。

A metered-dose inhaler is a device that delivers medication into the lungs through a pressurized canister. It can be released manually or automatically when inhaled. Some inhalers have counters to track remaining doses. Dry powder inhalers (DPI) are breath-activated, releasing medication only when a deep, fast breath is taken through the inhaler.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

The market for metered dose inhalers (MDIs) is growing due to technological advancements. Modern MDIs feature integrated dose counters, smart connectivity, and breath-actuated mechanisms, addressing issues like improper dosage and patient adherence. These innovations are particularly beneficial for chronic conditions like asthma and COPD. The shift to environmentally friendly propellants aligns with global sustainability goals and ensures effective drug delivery. These improvements are enhancing user experience, safety, and therapeutic outcomes, driving demand for advanced MDIs.

For instance, in June 2024, Aseptika has launched the PUFFClicker3, a smart inhaler dose tracker compatible with both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI). The device supports 101 SNOMED-coded inhalers for both types, making inhaler switching a simple process. It provides graphical instructions for each inhaler, aiming to improve inhaler adherence for patients of all ages and respiratory conditions requiring inhaler treatment.

Stringent Regulatory Requirements

The global metered-dose inhalers market faces significant challenges due to stringent regulatory requirements from authorities like the FDA and EMA. These regulations mandate rigorous testing protocols to ensure safety, efficacy, and quality of MDIs. Transitioning to eco-friendly propellants has complicated the approval process, requiring extensive research and compliance measures. Delays in regulatory approvals can hinder product launches, impacting market dynamics. Variations in regulatory frameworks across regions also pose challenges for global expansion, creating barriers for both established and emerging players, limiting innovation and market growth.

Segment Analysis

The global metered-dose inhalers market is segmented based on product type, application, end user and region.

Product type:

Breath-Actuated Pressurized Inhalers segment is expected to dominate the metered-dose inhalers market share

The breath-actuated pressurized segment holds a major portion of the metered-dose inhalers market share and is expected to continue to hold a significant portion of the metered-dose inhalers market share during the forecast period.

Breath-actuated pressurized metered-dose inhalers (BAIs) are gaining prominence in the global MDI market due to their ability to address the challenge of coordination between inhalation and actuation. Traditional MDIs require patients to synchronize their breathing with the device's drug release, which can be difficult for certain populations, such as elderly patients and children. BAIs automatically release medication when the patient inhales, ensuring optimal drug delivery and improving therapeutic outcomes. They are particularly useful for chronic respiratory conditions like asthma and COPD, where long-term treatment compliance is crucial.

For instance, in November 2023, Berry Global Healthcare has introduced the PneumoHaler, a lightweight, breath-actuated inhaler designed for managing asthma and COPD. This multi-dose inhaler is designed to eliminate the need for pharmaceutical companies to develop their own platforms, allowing faster-to-market solutions. The PneumoHaler also improves medication administration by addressing poor user technique of pressurized metered dose inhalers.

Application:

Asthma segment is the fastest-growing segment in metered-dose inhalers market share

The asthma segment is the fastest-growing segment in the metered-dose inhalers market share and is expected to hold the market share over the forecast period.

Asthma is a major global market driver due to its high prevalence and the need for long-term management solutions. With over 260 Billion people affected by asthma, the demand for MDIs is increasing due to factors like urbanization, air pollution, and climate change. MDIs provide rapid drug delivery to the airways, relieving symptoms like wheezing and chest tightness. Advanced formulations, such as corticosteroids and combination therapies, have expanded treatment options. Government health initiatives and awareness campaigns support early diagnosis and management of asthma, further boosting demand for MDIs. Asthma's global burden directly influences the MDI market's growth trajectory.

For instance, in July 2023, Lupin has introduced Luforbec, a pressurized metered dose inhaler, for the treatment of asthma and COPD in Germany. Hormosan Pharma GmbH, a subsidiary of Lupin, has introduced Luforbec in the country. The product is suitable for adult asthma and COPD treatment, where an inhaled corticosteroid and long-acting beta2-agonist is used.

Geographical Analysis

North America is expected to hold a significant position in the metered-dose inhalers market share

North America holds a substantial position in the metered-dose inhalers market and is expected to hold most of the market share due to the rising prevalence of respiratory diseases like asthma and COPD in North America, combined with an aging population, has led to a greater need for effective treatment options. MDIs are one of the most commonly prescribed devices for managing these conditions. The high level of healthcare awareness, better access to medical facilities, and well-established healthcare infrastructure in the region support the demand for advanced inhaler technologies. Major pharmaceutical companies in North America continuously innovate to improve inhaler designs and formulations, including smart inhalers with dose counters and tracking capabilities, which improve patient compliance and make MDIs the treatment of choice for many.

For instance, according to National Heart, Lung and Blood Institute, COPD, a combination of emphysema and chronic bronchitis, affects over 14 billion adults in the US, with over half being women. The severity of each condition varies. COPD rates are higher in American Indian and Alaska Native communities and rural areas. It is a major cause of disability and the sixth leading cause of death in the US, according to the Centers for Disease Control and Prevention.

Europe is growing at the fastest pace in the metered-dose inhalers market

Europe holds the fastest pace in the metered-dose inhalers market and is expected to hold most of the market share due to the FDA approvals, increasing prevalence of respiratory diseases like asthma and COPD. The aging population and increased exposure to environmental pollutants contribute to this demand. The European Union's strict regulatory standards, focusing on eco-friendly propellants and sustainability, are driving innovation in the inhaler market. Government initiatives promoting early diagnosis and effective management of these diseases further support MDI demand. Healthcare reimbursement systems in Europe ensure patients have access to necessary treatments, including MDIs.

For instance, in January 2024, Avillion LLP, a drug development company, has received FDA approval for AstraZeneca's Airsupra, a first-in-class, pressurised metered-dose inhaler (pMDI) and rescue medication. Airsupra is designed to treat bronchoconstriction and reduce exacerbations in people aged 18 and older with asthma. The FDA approved Airsupra, which contains albuterol and budesonide, a short-acting beta2-agonist.

Moreover, the region's focus on medical technology and collaborations between healthcare institutions and pharmaceutical companies has led to continuous improvements in MDI design, enhancing user experience and therapeutic efficacy.

Competitive Landscape

The major global players in the metered-dose inhalers market include Sunovion Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim, Covis Pharma B.V., GlaxoSmithKline, Kindeva Drug Delivery LP, Teva Phamrmaceuticals, Norton Waterford LTD, Armstrong Pharmaceuticals Inc, Cipla LTD and among others.

Key Developments

In November 2023, GSK plc is set to begin Phase III trials of a low carbon version of its metered dose inhaler, Ventolin (salbutamol), in 2024. If successful, it could reduce greenhouse gas emissions by around 90%, contributing to GSK's net-zero climate targets. The inhaler, used by 35 Billion patients worldwide, accounts for 49% of GSK's carbon footprint and contributes to global health systems' carbon footprint. Reducing the propellant's carbon footprint is a key milestone in the company's journey to net zero.
In September 2024, AstraZeneca has completed studies for the transition of Breztri/Trixeo Aerosphere, a triple-combination therapy for chronic obstructive pulmonary disease, to a new propellant with 99.9% lower Global Warming Potential than current inhaled medicines. Breztri will be the first medicine in AstraZeneca's pressurised-metered dose inhalers (pMDIs) to transition to the new propellant. Clinical programs are underway for the transition of AstraZeneca's wider pMDI portfolio.

Emerging Players

The emerging players in the metered-dose inhalers market include Propeller Health (digital inhaler technology), Adherium (smart inhaler systems), Amiko Digital Health Limited and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global metered-dose inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Stringent Regulatory Requirements
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
- 6.1.2. Market Attractiveness Index, By Product type
6.2. Breath-Actuated Pressurized Inhalers*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Manually-Actuated Pressurized Inhalers
6.4. Soft Mist Inhalers

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Asthma*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chronic Obstructive Pulmonary Disease (COPD)
7.4. Others

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospital Pharmacies*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Sunovion Pharmaceuticals Inc*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. AstraZeneca
11.3. Boehringer Ingelheim
11.4. Covis Pharma B.V.
11.5. GlaxoSmithKline
11.6. Kindeva Drug Delivery LP
11.7. Teva Phamrmaceuticals
11.8. Norton Waterford LTD
11.9. Armstrong Pharmaceuticals Inc
11.10. Cipla LTD

LIST NOT EXHAUSTIVE